newsfilter
← Latest News
GlobeNewswire·

Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain

FX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogelProof-of-concept trial will evaluate safety and tolerability of...